Clinical trials: Retinal Dystrophy
Retinal Degeneration, Retinitis Pigmentosa
Stem Cells Therapy in Degenerative Diseases of the Retina
The purpose of this study is to test the safety and effectiveness of an autologous bone marrow-derived stem/progenitor cells administered intravitreously in the subjects with degenerative diseases of the retina.
- Conditions
- Retinal Degeneration, Retinitis Pigmentosa, Age Related Macular Degeneration, Stargardt Disease 1
- Trial name
- NCT03772938
- Testing
- Stem/progenitor cells transplantation
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Pomeranian Medical University Szczecin
Retinitis Pigmentosa
Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients
This is zM-02's safety, tOlerability, and efficacy in retinitis pigmentOsa first-in-humaN study (MOON). This trial is meant to evaluate the safety and efficacy of ZM-02 in Retinitis pigmentosa (RP) patients.
- Trial name
- MOON (NCT06292650)
- Testing
- ZM-02-L, ZM-02-H, ZM-02-S
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Zhongmou Therapeutics
Stargardt Disease
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
The purpose of the study is to evaluate the safety and effects of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) in Subjects with Stargardt Disease
- Trial name
- STARLIGHT (NCT05417126)
- Testing
- Gene Therapy-vMCO-010
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Nanoscope Therapeutics Inc.
Hearing Disorder
Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan
Objective: One objective of this study is to genetically map and identify mutated genes for human hereditary hearing loss. A second objective is to study the function of these genes in the auditory system using mouse models.
- Trial name
- NCT00341874
- Where
- Pakistan
- Volunteers
- 18,009 people
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Retinitis Pigmentosa (RP)
UGX202 Injection in Patients With Advanced Retinitis Pigmentosa
The primary objective of this clinical trial is to evaluate the safety and tolerability of a single intravitreal injection of the gene therapy drug UGX202 in patients with advanced RP.
- Trial name
- NCT07311863
- Testing
- UGX202 injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Suzhou UgeneX Therapeutics Co., Ltd.
Retinitis Pigmentosa
Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
The purpose of this trial is to determine whether a nutritional supplement in addition to vitamin A will slow the course of retinitis pigmentosa.
- Trial name
- NCT00000116
- Testing
- Vitamin A, Docosahexaenoic acid, Control fatty acid
- Where
- United States
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Carol Weigel DiFranco
Retinitis Pigmentosa
Promising ROd-cone DYstrophy Gene therapY
This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a…
- Trial name
- PRODYGY (NCT05748873)
- Testing
- SPVN06
- Where
- 6 sites in United States, France
- Volunteers
- 33 people
- Sponsor
- SparingVision
Retinitis Pigmentosa (RP)
Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)
Retinitis pigmentosa (RP) is the most common hereditary retinal disorder (accounts for 20% of children attending blind schools in Pakistan) which causes degeneration of rod and cone photoreceptors.
- Trial name
- NCT04763369
- Testing
- Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa, Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Jinnah Burn and Reconstructive Surgery Centre, Lahore
Retinitis Pigmentosa
Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)
This research study is being done to learn what effect 12 months of treatment with oral hydroxychloroquine (HCQ) will have on the retina in people with retinitis pigmentosa (RP).
- Trial name
- NCT04120883
- Testing
- Hydroxychloroquine lower dose, Hydroxychloroquine higher dose
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Michigan
Macular Dystrophy
Correlation Between OCT and Mf-ERG Findings With BCVA in Patients With Macular Dystrophy
Correlation between optical coherence tomography and multifocal electroretinogram findings with visual acuity in patients with macular dystrophy.
- Trial name
- NCT07171541
- Testing
- OCT ,mFERG,VA test
- Volunteers
- 30 people
- Sponsor
- New Valley University
Leber Congenital Amaurosis
Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)
A clinical trial of AAV2/5 vector for patients with Defects in RPE65
- Trial name
- OPTIRPE65 (NCT02781480)
- Testing
- AAV RPE65
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 15 people
- Sponsor
- MeiraGTx UK II Ltd
Vision Functional Brain Networks in Patients With Hereditary Retinal Dystrophies
VIsual Cerebral ConnecTivity On Functional Magnetic Resonance Imaging in Patients With Hereditary REtinal Dystrophies
The Rothschild Foundation A Hospital follows a cohort of approximately 300 patients with hereditary retinal dystrophy. These patients are followed in ophthalmology consultation every year.
- Trial name
- VICTOIRE (NCT04648124)
- Testing
- IRMf-r (séquence resting state)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Bardet-Biedl Syndrome
Characterizing the Genotype and Phenotype in Adults With Bardet-Biedl Syndrome
Bardet-Biedl syndrome (BBS; OMIN #209900) is a rare genetic disorder characterized by six core features: rod-cone dystrophy (retinitis pigmentosa), polydactyly, obesity, genital anomalies, renal anomalies, and learning…
- Trial name
- NCT05400278
- Testing
- No intervention
- Where
- Norway
- Volunteers
- 30 people
- Sponsor
- Oslo University Hospital
Retinitis Pigmentosa, Stem Cell Transplant
Spheroidal Mesenchymal Stem Cells in Retinitis Pigmentosa
Purpose: This prospective clinical case series aimed to evaluate the effect of suprachoroidal implantation of mesenchymal stem cells (MSCs) in the form of spheroids as a stem cell therapy for retinitis pigmentosa (RP) patients…
- Trial name
- NCT05712148
- Testing
- Stem cell implantation
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Acibadem University
Choroidal Ischemia, Vitelliform Macular Dystrophy
Sildenafil for Treatment of Choroidal Ischemia
The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform degeneration, dry and…
- Conditions
- Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy
- Trial name
- NCT04356716
- Testing
- Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Columbia University
Bietti Crystalline Dystrophy, Inherited Retinal Diseases
Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy
This is a phase 3 study to evaluate the efficacy and safety of VGR-R01 in subjects with Bietti Crystalline Dystrophy. This is a multicenter, randomized controlled study which will enroll 45 subjects.
- Trial name
- NCT06699108
- Testing
- VGR-R01
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
Retinitis Pigmentosa (RP), Usher Syndrome
24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001.
- Trial name
- NCT07290530
- Testing
- N-acetylcysteine amide
- Volunteers
- 80 people
- Sponsor
- Nacuity Pharmaceuticals, Inc.
Stargardt Disease
The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy
While a fair amount of clinical data on Stargardt disease type 1 (STGD1) have been published, very little is known about Stargardt disease type 4 (STGD4).
- Trial name
- ProgStar-4 (NCT02410122)
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 15 people
- Sponsor
- Johns Hopkins University
Retinitis Pigmentosa
TES for the Treatment of RP
Retinitis pigmentosa (RP) is a progressive degenerative disease of the retina, which often leads to blindness. 1 in 4000 people in the UK are affected by RP yet there is no established therapy for treating or delaying its…
- Trial name
- TESOLAUK (NCT01847365)
- Testing
- Transcorneal electrical stimulation
- Where
- 2 sites in United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Retinitis Pigmentosa (RP)
Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa
Retinitis pigmentosa (RP) is a rare inherited retinal degenerative disease that causes progressive visual field loss and vision impairment, often leading to blindness.
- Trial name
- RP CLARITI (NCT07774975)
- Testing
- ULREA-PVS-NP
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Kyushu University